NOXXON Announces Initiation Of First-in-Human Clinical Trial With Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer® NOX-A12. NOX-A12 is NOXXON’s second drug candidate entering the clinical stage of development within only five months.
[Read the full article here]Related News:
CYT107 Promotes T-Cell Recovery After T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Athersys Announces Positive Results of MultiStem Clinical Trial for Hematopoietic Stem Cell Transplant Support and …
Fate Therapeutics Announces First Patient Treated In Phase 1b Clinical Trial Of FT1050 For Hematopoietic Stem Cell …